Tumor-derived heat shock protein 70-pulsed dendritic cells elicit-tumor-specific cytotoxic T lymphocytes (CTLs) and tumor immunity

Cancer Science

Volumn 95, Issue 3, 2004, Pages 248-253

  Ueda, Gosei ^a,b   Tamura, Yasuaki ^a   Hirai, Itaru ^a   Kamiguchi, Kenjirou ^a   Ichimiya, Shingo ^a   Torigoe, Toshihiko ^a   Hiratsuka, Hiroyoshi ^b   Sunakawa, Hajime ^b   Sato, Noriyuki ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF THE RYUKYUS   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HEAT SHOCK PROTEIN 70; IMMUNOMODULATING AGENT; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTATION; ARTICLE; BONE MARROW CELL; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PATIENT; COMPLEX FORMATION; CONTROLLED STUDY; CROSS REACTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG ACTIVITY; DRUG ANTIGENICITY; DRUG EFFICACY; EVIDENCE BASED MEDICINE; FEMALE; IMMUNE RESPONSE; INTERNALIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR IMMUNITY;

ANIMALS; ANTIGEN PRESENTATION; CELL LINE, TUMOR; DENDRITIC CELLS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HSP70 HEAT-SHOCK PROTEINS; LYMPHOCYTE ACTIVATION; MASTOCYTOMA; MICE; MICROSCOPY, CONFOCAL; T-LYMPHOCYTES, CYTOTOXIC;

EID: 1842867003     PISSN: 13479032     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2004.tb02211.x     Document Type: Article

References (23)

1. Srivastava P. Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses. Annu Rev Immunol 2002; 20: 395-425.
2. Udono H, Levey DL, Srivastava PK. Cellular requirements for tumor-specific immunity elicited by heat shock proteins: tumor rejection antigen gp96 primes CD8+ T cells in vivo. Proc Natl Acad Sci USA 1994; 91: 3077-81.
3. Udono H, Srivastava PK. Comparison of tumor-specific immunogenicities of stress-induced proteins gp96, hsp90, and hsp70. J Immunol 1994; 152: 5398-403.
4. Tamura Y, Peng P, Liu K, Daou M, Srivastava PK. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science 1997; 278: 117-20.
5. Sato K, Torimoto Y, Tamura Y et al. Immunotherapy using heat-shock protein preparations of leukemia cells after syngeneic bone marrow transplantation in mice. Blood 2001; 98: 1852-7.
6. Kojima T, Yamazaki K, Tamura Y et al. Granulocyte-macrophage colony-stimulating factor gene-transduced tumor cells combined with tumor-derived gp96 inhibit tumor growth in mice. Hum Gene Ther 2003; 14: 715-28.
7. Binder R, Han D, Srivastava P. CD91: a receptor for heat shock protein gp96. Nature Immunol 2000; 1: 151-5.
8. Castellino F, Boucher PE, Eichelberg K et al. Receptor-mediated uptake of antigen/heat shock protein complexes results in major histocompatibility complex class I antigen presentation via two distinct processing pathways. J Exp Med 2000; 191: 1957-64.
9. Noessner E, Gastpar R, Milani V et al. Tumor-derived heat shock protein 70 peptide complexes are cross-presented by human dendritic cells. J Immunol 2002; 169: 5424-32.
10. Castelli C, Ciupitu AM, Rini F et al. Human heat shock protein 70 peptide complexes specifically activate antimelanoma T cells. Cancer Res 2001; 61: 222-7.
11. Berwin B, Rosser MF, Brinker KG, Nicchitta CV. Transfer of GRP94(Gp96)-associated peptides onto endosomal MHC class I molecules. Traffic 2002; 3: 358-66.
12. Arnold-Schild D, Hanau D, Spehner D et al. Cutting edge: receptor-mediated endocytosis of heat shock proteins by professional antigen-presenting cells. J Immunol 1999; 162: 3757-60.
13. Becker T, Hartl FU, Wieland F. CD40, an extracellular receptor for binding and uptake of Hsp70-peptide complexes. J Cell Biol 2002; 158: 1277-85.
14. Delneste Y, Magistrelli G, Gauchat J et al. Involvement of LOX-1 in dendritic cell-mediated antigen cross-presentation. Immunity 2002; 17: 353-62.
15. Van den Eynde B, Lethe B, Van Pel A, De Plaen E, Boon T. The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice. J Exp Med 1991; 173: 1373-84.
16. Lethe B, van den Eynde B, van Pel A, Corradin G, Boon T. Mouse tumor rejection antigens P815A and P815B: two epitopes carried by a single peptide. Eur J Immunol 1992; 22: 2283-8.
17. Bilsborough J, Van Pel A, Uyttenhove C, Boon T, Van den Eynde BJ. Identification of a second major tumor-specific antigen recognized by CTLs on mouse mastocytoma P815. J Immunol 1999; 162: 3534-40.
18. Ciupitu AM, Petersson M, O'Donnell CL et al. Immunization with a lymphocytic choriomeningitis virus peptide mixed with heat shock protein 70 results in protective antiviral immunity and specific cytotoxic T lymphocytes. J Exp Med 1998; 187: 685-91.
19. Binder RJ, Blachere NE, Srivastava PK. Heat shock protein-chaperoned peptides but not free peptides introduced into the cytosol are presented efficiently by major histocompatibility complex I molecules. J Biol Chem 2001; 276: 17163-71.
20. Zwaveling S, Ferreira Mota SC, Nouta J et al. Established human papilloma-virus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J Immunol 2002; 169: 350-8.
21. Singh-Jasuja H, Toes RE, Spee P et al. Cross-presentation of glycoprotein 96-associated antigens on major histocompatibility complex class I molecules requires receptor-mediated endocytosis. J Exp Med 2000; 191: 1965-74.
22. Basu S, Binder RJ, Ramalingam T, Srivastava PK. CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity 2001; 14: 303-13.
23. Rodriguez A, Regnault A, Kleijmeer M et al. Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells. Nat Cell Biol 1999; 1: 362-8.